Amgen sales rose by 5% in Q1

Share this article:

First-quarter Kyprolis sales of $68 million helped increase Amgen's first-quarter sales by 5% compared to the same period last year.

While the biotech saw increased demand and sales for drugs, including bone biologic Prolia and anemia product Epogen, demand and sales declined for some brands, with sales of RA shot Enbrel slipping 5% and kidney drug Aranesp sales falling 2% compared to the same period last year. The company attributed some of this fall-off to inventory draw-down.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions